111 related articles for article (PubMed ID: 22128433)
21. Reducing attrition in drug development: smart loading preclinical safety assessment.
Roberts RA; Kavanagh SL; Mellor HR; Pollard CE; Robinson S; Platz SJ
Drug Discov Today; 2014 Mar; 19(3):341-7. PubMed ID: 24269835
[TBL] [Abstract][Full Text] [Related]
22. Predicting safety toleration of pharmaceutical chemical leads: cytotoxicity correlations to exploratory toxicity studies.
Benbow JW; Aubrecht J; Banker MJ; Nettleton D; Aleo MD
Toxicol Lett; 2010 Sep; 197(3):175-82. PubMed ID: 20576494
[TBL] [Abstract][Full Text] [Related]
23. Preclinical safety evaluation of recombinant human interleukin-10.
Rosenblum IY; Johnson RC; Schmahai TJ
Regul Toxicol Pharmacol; 2002 Feb; 35(1):56-71. PubMed ID: 11846636
[TBL] [Abstract][Full Text] [Related]
24. [Significance of ICH--toxicokinetics guidance and its practice--a useful approach for safety drug development].
Tsuda M; Ohno Y
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 1997; (115):1-14. PubMed ID: 9641814
[TBL] [Abstract][Full Text] [Related]
25. Applications of emerging technologies in toxicology and safety assessment.
Reynolds VL
Int J Toxicol; 2005; 24(3):135-7. PubMed ID: 16040564
[TBL] [Abstract][Full Text] [Related]
26. Issues in the design and interpretation of chronic toxicity and carcinogenicity studies in rodents: approaches to dose selection.
Rhomberg LR; Baetcke K; Blancato J; Bus J; Cohen S; Conolly R; Dixit R; Doe J; Ekelman K; Fenner-Crisp P; Harvey P; Hattis D; Jacobs A; Jacobson-Kram D; Lewandowski T; Liteplo R; Pelkonen O; Rice J; Somers D; Turturro A; West W; Olin S
Crit Rev Toxicol; 2007; 37(9):729-837. PubMed ID: 17957539
[TBL] [Abstract][Full Text] [Related]
27. Collaborative study on fifteen compounds in the rat-liver Comet assay integrated into 2- and 4-week repeat-dose studies.
Rothfuss A; O'Donovan M; De Boeck M; Brault D; Czich A; Custer L; Hamada S; Plappert-Helbig U; Hayashi M; Howe J; Kraynak AR; van der Leede BJ; Nakajima M; Priestley C; Thybaud V; Saigo K; Sawant S; Shi J; Storer R; Struwe M; Vock E; Galloway S
Mutat Res; 2010 Sep; 702(1):40-69. PubMed ID: 20656055
[TBL] [Abstract][Full Text] [Related]
28. Predictive value of preclinical toxicology studies for platinum anticancer drugs.
Clark DL; Andrews PA; Smith DD; DeGeorge JJ; Justice RL; Beitz JG
Clin Cancer Res; 1999 May; 5(5):1161-7. PubMed ID: 10353752
[TBL] [Abstract][Full Text] [Related]
29. Preclinical formulations for discovery and toxicology: physicochemical challenges.
Neervannan S
Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):715-31. PubMed ID: 17014391
[TBL] [Abstract][Full Text] [Related]
30. A brief survey of first-in-human studies.
Wexler D; Bertelsen KM
J Clin Pharmacol; 2011 Jul; 51(7):988-93. PubMed ID: 20671293
[TBL] [Abstract][Full Text] [Related]
31. [Pharmacokinetic and metabolic studies in the development of drugs].
Vereczkey L
Acta Pharm Hung; 1995 Jul; 65(4):105-11. PubMed ID: 7572191
[TBL] [Abstract][Full Text] [Related]
32. Juvenile animal toxicity study designs to support pediatric drug development.
Cappon GD; Bailey GP; Buschmann J; Feuston MH; Fisher JE; Hew KW; Hoberman AM; Ooshima Y; Stump DG; Hurtt ME
Birth Defects Res B Dev Reprod Toxicol; 2009 Dec; 86(6):463-9. PubMed ID: 20025047
[TBL] [Abstract][Full Text] [Related]
33. What have we learned from pre-clinical juvenile toxicity studies?
Bailey GP; Mariën D
Reprod Toxicol; 2009 Sep; 28(2):226-9. PubMed ID: 19446432
[TBL] [Abstract][Full Text] [Related]
34. Toxicity assessment strategies, data requirements, and risk assessment approaches to derive health based guidance values for non-relevant metabolites of plant protection products.
Dekant W; Melching-Kollmuss S; Kalberlah F
Regul Toxicol Pharmacol; 2010 Mar; 56(2):135-42. PubMed ID: 19883711
[TBL] [Abstract][Full Text] [Related]
35. Optimising the design of preliminary toxicity studies for pharmaceutical safety testing in the dog.
Smith D; Combes R; Depelchin O; Jacobsen SD; Hack R; Luft J; Lammens L; von Landenberg F; Phillips B; Pfister R; Rabemampianina Y; Sparrow S; Stark C; Stephan-Gueldner M
Regul Toxicol Pharmacol; 2005 Mar; 41(2):95-101. PubMed ID: 15698532
[TBL] [Abstract][Full Text] [Related]
36. Clinical pharmacokinetics: current requirements and future perspectives from a regulatory point of view.
Shah RR
Xenobiotica; 1993 Nov; 23(11):1159-93. PubMed ID: 8310705
[TBL] [Abstract][Full Text] [Related]
37. Evaluations of organ system development in juvenile toxicology testing.
Robinson K
Reprod Toxicol; 2008 Sep; 26(1):51-3. PubMed ID: 18595655
[TBL] [Abstract][Full Text] [Related]
38. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
Vaughan D; Speed J; Medve R; Andrews JS
Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
[TBL] [Abstract][Full Text] [Related]
39. Use of the dog as non-rodent test species in the safety testing schedule associated with the registration of crop and plant protection products (pesticides): present status.
Box RJ; Spielmann H
Arch Toxicol; 2005 Nov; 79(11):615-26. PubMed ID: 15940470
[TBL] [Abstract][Full Text] [Related]
40. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
Kuentz M; Nick S; Parrott N; Röthlisberger D
Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
